Ultragenyx Pharmaceutical Inc (RARE) - News Archive

Ultragenyx Pharmaceutical Inc. has reported positive longer-term data from a Phase 3 clinical study evaluating DTX401, an adeno-associated virus (AAV) gene therapy, for the treatment of Glycogen Storage Disease Type Ia...

Investor Alert: Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc. Amidst Unfavourable Market Performance The Pomerantz Law Firm has initiated an investigation into claims on behalf of investors of Ultrageny...

Ultragenyx Pharmaceutical Inc. Strengthens Workforce and Growth Potential Through Strategic Stock Grant InitiativesOn March 19, 2025, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializi...

Ultragenyx Enhances Workforce with Stock Incentives - What This Means for ShareholdersNOVATO, Calif. Feb. 19, 2025 In a strategic move aimed at attracting top talent, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), known...

In a strategic move to bolster its management team, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a prominent player in the biopharmaceutical sector focused on developing therapies for rare diseases, announced the gran...

Ultragenyx Pharmaceutical s Groundbreaking Development in Pediatric HoFH Treatment Amidst Operational Challenges IntroductionIn a significant advancement for pediatric healthcare, the European Commission (EC) has extend...

In a strategic move aimed at bolstering its leadership infrastructure, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a pioneering biopharmaceutical entity dedicated to the development of innovative therapies for rare a...

The landscape of treatment for rare genetic diseases continues to evolve, marked by the recent commissioning of Evkeeza (evinacumab) by NHS England for patients with homozygous familial hypercholesterolaemia (HoFH) aged...

Ultragenyx Pharmaceutical Inc. a leader in the development of innovative gene therapies for rare genetic diseases, has made a significant move in the field of genetic therapeutics with the submission of a Biologics Lice...

Ultragenyx Pharmaceutical Inc.: Navigating Employee Incentives and Market Dynamics in the Rare Disease SectorIn a strategic move aimed at fortifying its talent base and enhancing employee retention, Ultragenyx Pharmaceu...

In a significant stride for patients with rare bone disorders, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a company committed to innovating treatments for rare and ultra-rare diseases, has proudly announced that it...

Novel Developments in Gene Therapy: Ultragenyx Updates on UX701 for Wilson Disease in Cyprus2+ Study Recent updates from Ultragenyx Pharmaceutical Inc. regarding their pivotal Phase 1/2/3 Cyprus2+ study highlight signif...

On September 3, 2024, OKX Explorer, a prominent blockchain search engine and analytics platform, announced the integration of support for Bitlayer, a platform designed for the management and analysis of blockchain data....

Ultragenyx Welcomes New Talent with Stock Incentives: A Strategic Move in the Biopharmaceutical SectorIn a significant move to enhance its workforce, Ultragenyx Pharmaceutical Inc. a leading biopharmaceutical company de...

Breaking Ground in Rare Disease Research: Ultragenyx s Impressive Advances for Angelman Syndrome, Osteogenesis Imperfecta, and Glycogen Storage Disease Type Ia Ultragenyx Pharmaceutical, a frontrunner in the biopharmace...

Ultragenyx Pharmaceutical Inc. Grants Inducement Stock Options to Newly Hired Non-Executive OfficersBy NOVATO, Calif. - Ultragenyx Pharmaceutical Inc., a leading biopharmaceutical company specializing in the development...

Ultragenyx Pharmaceuticals recently disclosed a successful outcome of their End-of-Phase 2 meeting with the US Food and Drug Administration (FDA). This crucial meeting discussed the future of Ultragenyx s GTX-102 Angelm...

Ultragenyx Pharmaceutical Inc., a leading biopharmaceutical company specializing in rare and ultrarare diseases, has recently made important announcements regarding its corporate growth strategy. The company reported th...

Ultragenyx Pharmaceutical Announces Underwritten Public Offering and Inducement Grants for Newly Hired Non-Executive OfficersNOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a leading biopharmaceutical co...

In a groundbreaking development, Ultragenyx Pharmaceutical Inc has recently announced its plans to file for accelerated approval of UX111 for the treatment of Sanfilippo Syndrome Type A (MPS IIIA). This announcement com...